Amgen stock costs EUR 371.30 on October 9, 2026 after EUR 360.08. Cantor Fitzgerald set a USD 440.00

Second-quarter revenue reached USD 10.05 billion versus USD 9.43 billion consensus. Amgen stock stoo

Mn Services Vermogensbeheer B.V. lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 159,819 shares of the medical research company

Farther Finance Advisors LLC raised its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,131 shares of the medical research company

Amgen stock costs EUR 362.13 on October 8, 2026 after EUR 368.60. Nasdaq price was USD 405.43 on Oct

Second-quarter revenue reached USD 10.05 billion. Amgen stock costs EUR 364.28 on October 8, 2026 af

Amgen (AMGN) stock has returned 44% over the past twelve months, easily outpacing the 17.1% gain for the S&P 500. Investors looking at that rally might question what catalysts remain to push shares higher. One candidate is an experimental therapy that is not yet on the market, and executives say its development is progressing rapidly. So what is that drug, and how far along is it.

During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones Industrial Average’s third-quarter performance. He then shifted his attention to Johnson & Johnson (NYSE:JNJ), as he said: In the end, I think the best lessons from the third quarter came from the 30 stocks in the […]

Bath Savings Trust Co raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2,509.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,147 shares of the medical research company

MRA Advisory Group lowered its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 66.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,441 shares of the medical research company

Worth Asset Management LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,337 shares of the medical research company

Amgen stock traded at USD 415.18 on October 7, 2026, with a USD 224.1 billion market capitalization.